“This phakic patient with cataracts was concerned about frequent injections for her DME. I chose ILUVIEN for this patient and her edema improved, and after cataract surgery she is seeing great.”

— Daniel M. Miller, MD, PhD

Results presented below are from a single case; results may vary.

Daniel M. Miller, MD, PhD

Board-certified Diplomate of the American Board of Ophthalmology and fellowship-trained retina specialist; Dr. Miller serves as the Medical Director of the Cincinnati Eye Institute.

Academic affiliations:

  • MD/PhD at the Ohio State University College of Medicine — graduated with recognition for academic excellence and national awards for his research contributions
  • Internship at Riverside Methodist Hospital in Columbus, Ohio
  • Ophthalmology residency and subspecialty training at the Bascom Palmer Eye Institute associated with the University of Miami School of Medicine

Patient profile 1

Sex: Female
Age: 68
Diagnosis: DME
Treated eye: OD
Concomitant conditions: High blood pressure
Treatment history:
• 2X Focal laser
• 14X Anti-VEGF
• 1X Corticosteroid
Notes: Phakic to pseudophakic

Reasons Dr. Miller chose ILUVIEN:

  • Multiple prior lasers and intravitreal injections without consistent control of swelling in the macula
  • Patient concern about frequent injections and results that were not optimal
  • Looking for a longer-acting treatment option

Patient outcome

  • No additional treatments for DME were required during nearly 1 year of follow-up post ILUVIEN
  • Visual acuity has improved
  • Good changes in optical coherence tomography (OCT)

“Since the patient’s ILUVIEN treatment, she has been extremely pleased, her visits are far less frequent than before ILUVIEN, and she does quite well with her vision.”

— Daniel M. Miller, MD, PhD

Retinal thickness (μm)

Best corrected visual acuity (BCVA)

Intraocular pressure (IOP) (mm Hg)

Selected OCT Scans


ILUVIEN injected
Visual Acuity: 20/30
Letters: 76
OCT: 511 μm
IOP: 16 mm Hg

Phakic Case
Phakic Case

Download a printable, pdf version of this case.

Phakic Data
Phakic Data

Review data from phakic patients in the ILUVIEN
Phase 3 clinical trials (FAME).